Supplemental Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter
Study Details
Study Description
Brief Summary
This study will include up to 60 eligible male and female subjects. The purpose of this trial is to evaluate the safety and effectiveness of the NovaCross™ micro-catheter when used to facilitate crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries. The procedure will be conducted on consenting patients diagnosed with a CTO in a coronary vessel that requires revascularization after a previously failed attempt to cross or refractory to 10 minutes of conventional guidewire attempt. This study is an extension study of Nitiloop's Pivotal study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The purpose of this trial is to evaluate the safety and effectiveness of the NovaCross™ micro-catheter when used to facilitate crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries. The procedure will be conducted on consenting patients diagnosed with a CTO in a coronary vessel that requires revascularization after a previously failed attempt to cross or refractory to 10 minutes of conventional guidewire attempt.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Interventional Interventional arm, where the NovaCross™ CTO micro-catheter will be placed in study subjects during the Total Occlusion opening procedure. |
Device: NovaCross™ Chronic Total Occlusion micro-catheter
The NovaCross™ micro catheter is a guidewire positioning and support micro catheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment. Investigators will use the NovaCross Micro catheter during a standard of care catheterization of patients diagnosed with coronary total occlusion.
|
Outcome Measures
Primary Outcome Measures
- Primary Safety Endpoint - Rate of In hospital MACE events [until discharge or 30 days, the sooner of the two]
defined as the composite of death, myocardial infarction (MI), or urgent revascularization (target vessel revascularization (TVR) or urgent coronary artery bypass surgery (CABG)).
- Primary Efficacy Endpoint - Intra-procedural technical success [during the procedure]
defined as the ability of the NovaCross™ microcatheter to successfully facilitate placement of a guidewire beyond a native coronary chronic total occlusion (CTO) in the true vessel lumen
Secondary Outcome Measures
- Rate of Lesion Crossing [during the procedure]
The ability to cross the lesion with a guidewire in the true lumen, effectively dilate the CTO lesion, and place a coronary stent with residual lumen stenosis of less than 30% while restoring antegrade TIMI 3 flow
- Guidewire Facilitation and rate of successful penetration to the CTO [during the procedure]
The ability of the NovaCross™ micro-catheter to facilitate a guidewire successfully penetrating the proximal cap of the CTO
- Crossability [during the procedure]
The effectiveness of the extendable portion in intra-CTO microcatheter crossability
- Investigator visualization and ease of use [during the procedure]
The ability to have full visualization of the NovaCross during the CTO procedure and assessing the usability of the device
- Myocardial Infraction (MI) Rate [up to 30 days]
In hospital MI rate
- Device Related Adverse Events [up to 30 days]
Device-related perforation at the site of target coronary lesion and/or its proximal reference segment
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult aged 25-80
-
Patient understands and has signed the study informed consent form
-
Patient has an angiographic documented Chronic Total Occlusion (i.e. >3 months occlusion duration) showing distal TIMI flow 0, with a reference diameter of at least 2 millimeters.
-
Left ventricle ejection fraction > 25%
Exclusion Criteria:
- Patient unable to give informed consent. 2. Elevated CK-MB or troponin at baseline 3. Patient is known or suspected not to tolerate the contrast agent 4. Chronic Total Occlusion is located in aorto-ostial location, SVG CTO, in-stent occlusion 5. Appearance of a fresh thrombus or intraluminal filling defects 6. Intolerance to Aspirin and/or inability to tolerate a second antiplatelet agent (Clopidogrel and Prasugrel and Ticagrelor) 7. Cardiac intervention within 4 weeks of the procedure 8. Severe renal insufficiency with eGFR<30 ml/min/1.72 m2 9. Congestive heart failure [New York Heart Association (NYHA) Class III\IV] CSA Class IV 10. Life expectancy < 2 years due to other illnesses 11. Acute or unstable medical disorder/disease that may cause a risk to patient, including: i. Recent myocardial infarction (MI) (within the past two weeks) ii. Significant anemia (e.g. hemoglobin < 8.0 mg / dl) iii. Recent major cerebrovascular event (history of stroke or TIA within 1 month)
- Severe uncontrolled systemic hypertension (e.g., >180/100 mmHg) v. Unstable angina requiring emergent percutaneous trans-luminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rabin Medical Center | Petach Tikva | Israel | ||
| 2 | Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie | Kraków | Poland | ||
| 3 | Belfast City Hospital | Belfast | United Kingdom |
Sponsors and Collaborators
- Nitiloop Ltd.
Investigators
- Principal Investigator: Simon Walsh, MD, Belfast Health and Social Care Trust
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NT-CLP-03